APOA2 and cancer: Cancer cells have an increased expression of SR-B1in relation to the expression on their non-malignant cells of origin [16, 17] and it is possible that this results in increased uptake of HDL by the cancer tissue which is an explanation for the reduction in serum ApoA-II in PDAC cases [1–3].